MOS
ALNY icon

MGO One Seven’s Alnylam Pharmaceuticals ALNY Stock Holding History

MGO One Seven’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258K Sell
780
-53
-6% -$18K 0.01% 1218
2025
Q4 		$331K Buy
833
+133
+19% +$58.9K 0.01% 1073
2025
Q3 		$319K Buy
+700
New +$285K 0.01% 1003
2019
Q1 		– Sell
-31
Closed -$2K – 461
2018
Q4 		$2K Buy
+31
New +$2.38K ﹤0.01% 1538
2018
Q1 		$2K Buy
16
+3
+23% +$387 ﹤0.01% 1516
2017
Q4 		$2K Buy
+13
New +$1.63K ﹤0.01% 1490

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MGO One Seven's ALNY Position: Q1 2026 in Review

MGO One Seven reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.4% in Q1 2026, selling an estimated $18K and leaving 780 shares worth $258K. The position accounts for 0.01% of the portfolio, ranked #1218.

MGO One Seven first reported a position in ALNY in Q4 2017 and has held it in 6 quarters since. The position peaked at $331K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • MGO One Seven held 780 shares of Alnylam Pharmaceuticals worth $258K as of Q1 2026.
  • MGO One Seven sold 53 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $18K.
  • Alnylam Pharmaceuticals made up 0.01% of MGO One Seven's portfolio in Q1 2026, its #1218 holding.
  • MGO One Seven first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 6 quarters since.
  • MGO One Seven's Alnylam Pharmaceuticals position peaked at $331K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on MGO One Seven's 13F filing for Q1 2026, filed 14 May 2026.